# Lactose India (NSE: LACTOSE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/LACTOSE · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹132 Cr, it ranks 2506th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 8.8% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹46 Cr (+64.8% year on year) and net profit ₹2 Cr (+193.8%), on a standalone basis. Promoters held 53.65% of the company as of 30 Jun 2026; 26.07% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹132 Cr |
| ROE | 8.8% (FY25) |
| ROCE | 14.7% (FY25) |
| Debt to equity | 0.96 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹46 Cr | +64.8% | ₹2 Cr | +193.8% | ₹1.49 |
| Q3 FY26 | ₹37 Cr | +28.0% | ₹1 Cr | +140.9% | ₹0.42 |
| Q2 FY26 | ₹41 Cr | +35.2% | ₹2 Cr | +6.4% | ₹1.71 |
| Q1 FY26 | ₹40 Cr | +34.4% | ₹2 Cr | −33.9% | ₹1.19 |
| Q4 FY25 | ₹28 Cr | −5.5% | ₹1 Cr | −73.3% | ₹0.51 |
| Q3 FY25 | ₹29 Cr | −11.9% | ₹0 Cr | −91.6% | ₹0.17 |
| Q2 FY25 | ₹30 Cr | +24.6% | ₹2 Cr | +150.6% | ₹1.61 |
| Q1 FY25 | ₹29 Cr | +7.2% | ₹2 Cr | +136.5% | ₹1.80 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹116 Cr | ₹5 Cr |
| FY24 | ₹114 Cr | ₹7 Cr |
| FY23 | ₹66 Cr | ₹1 Cr |
| FY22 | ₹46 Cr | ₹2 Cr |
| FY21 | ₹35 Cr | −₹2 Cr |
| FY20 | ₹40 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 53.65%
- Domestic institutions: 0.62%
- Non-institutions: 45.74%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Smruthi Organic](https://app.pivotnow.in/stock/SMRUTHIORG) | — | ₹135 Cr | — | — |
| [Valencia Nutrit](https://app.pivotnow.in/stock/VALENCIA) | — | ₹132 Cr | — | — |
| [Par Drugs And Chemicals](https://app.pivotnow.in/stock/PAR) | ₹105.25 | ₹130 Cr | 9.9 | — |
| [Aspira Pathlab](https://app.pivotnow.in/stock/ASPIRA) | — | ₹125 Cr | — | — |
| [Parnax Lab](https://app.pivotnow.in/stock/PARNAXLAB) | ₹108.95 | ₹125 Cr | 10.6 | — |
| [Krebs Biochemicals and Industries](https://app.pivotnow.in/stock/KREBSBIO) | ₹57.16 | ₹123 Cr | — | — |

## Questions and answers

### What is the market cap of Lactose India?

Lactose India's market capitalisation is ₹132 Cr (₹132 Cr) at the 19 Oct 2026 close, ranking 2506th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Lactose India?

Return on equity was 8.8% in FY25 and return on capital employed was 14.7% in FY25 (standalone figures).

### Is Lactose India a debt-free company?

No. Lactose India's debt-to-equity ratio was 0.96 in FY25, with total debt of ₹26 Cr.

### What were Lactose India's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Lactose India reported revenue of ₹46 Cr, +64.8% year on year, and net profit of ₹2 Cr, +193.8% year on year.

### What is the shareholding pattern of Lactose India?

As of 30 Jun 2026: promoters 53.65%, domestic institutions 0.62%, non-institutions 45.74%. 26.07% of promoter shares were pledged.

### Who are Lactose India's competitors?

The listed Pharma & Healthcare companies closest to Lactose India by market cap are Smruthi Organic, Valencia Nutrit, Par Drugs And Chemicals, Aspira Pathlab, Parnax Lab and Krebs Biochemicals and Industries.

### Is Lactose India a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Lactose India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LACTOSE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.